Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;31(3):179-191.
doi: 10.1055/s-0037-1602238. Epub 2018 Apr 1.

Emerging Systemic Therapies for Colorectal Cancer

Christine M Veenstra  1 , John C Krauss  1
Affiliations
Review

Emerging Systemic Therapies for Colorectal Cancer

Christine M Veenstra et al. Clin Colon Rectal Surg. 2018 May.

Abstract

Despite advances over the past 20 years in colorectal cancer (CRC) screening, diagnosis, and treatment, survival outcomes remain suboptimal. Five-year survival for patients with locally advanced CRC is 69%; 5-year survival drops to 12% for patients with metastatic disease. Novel, effective systemic therapies are needed to improve long-term outcomes. In this review, we describe currently available systemic therapies for the treatment of locally advanced and metastatic CRC and discuss emerging therapies, including encouraging advances in identifying novel targeted agents and exciting responses to immunotherapeutic agents.

Keywords: clinical trials; colorectal cancer; emerging therapies; immunotherapy; targeted therapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
T cell targets for immune checkpoint inhibition and modulation. T cell stimulation is enhanced by antibodies that block inhibitory receptors or upregulate activating receptors. (Adapted from Mellman et al; Nature 2011;480:480–489.)
See this image and copyright information in PMC

References

    1. Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(01):7–30. - PubMed
    1. American Cancer Society.Cancer Facts & Figures 2016Atlanta: American Cancer Society;2016. Available at:http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2.... Accessed March 18, 2016
    1. Haggar F A, Boushey R P. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(04):191–197. - PMC - PubMed
    1. Kopetz S, Chang G J, Overman M J et al.Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–3683. - PMC - PubMed
    1. André T, Boni C, Navarro M et al.Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116. - PubMed